Form 4: Astria Therapeutics Director Fred Callori Granted 26,550 Stock Options
Insider Transaction Report
Astria Therapeutics, Inc. Director Fred Callori was granted 26,550 stock options with an exercise price of $5.79, vesting in one year.
Summary
- Fred Callori, a Director of Astria Therapeutics, Inc. (ATXS), was granted 26,550 stock options.
- The transaction date for the option grant was June 11, 2025.
- The exercise price for these stock options is $5.79 per share.
- The options will vest in their entirety on the one-year anniversary of the grant date, subject to Mr. Callori's continued service.
- The expiration date for these stock options is June 10, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While it's a routine compensation event, it signifies continued alignment of a director's interests with shareholder value through equity incentives.
Positives
- The grant of stock options to a director aligns management's interests with those of shareholders, as the options' value is tied to the company's stock performance.
Future Outlook
N/A This Form 4 filing primarily reports an insider transaction and does not provide forward-looking statements or guidance on company performance.
Industry Context
N/A This Form 4 filing is specific to an insider transaction and does not provide broader industry context.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Practice | Grant of stock options to a director as part of their compensation package, which is a standard corporate governance practice to incentivize long-term performance and align interests. | 06/11/2025 | Aligns director's financial interests with the long-term performance of the company's stock, potentially encouraging decisions that enhance shareholder value. |
Related Party Transactions
- The grant of 26,550 stock options to Fred Callori, a director of Astria Therapeutics, Inc., constitutes a related party transaction as part of his compensation.
Stakeholder Impact
- Shareholders: The grant of options to a director aims to align the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved long-term value creation.
Next Steps
- The stock options will vest on June 11, 2026, contingent on Fred Callori's continued service as a director.
Key Dates
| Date | Description |
|---|---|
| 06/11/2025 | Date of stock option grant to Fred Callori. |
| 06/12/2025 | Date the Form 4 was signed by Fred Callori's attorney-in-fact. |
| 06/11/2026 | One-year anniversary of the grant date, when the stock options will vest in their entirety, subject to continued service. |
| 06/10/2035 | Expiration date of the granted stock options. |
Keywords
Astria Therapeutics, ATXS, Fred Callori, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.